CMBA
VNDA icon

C.M. Bidwell & Associates’s Vanda Pharmaceuticals VNDA Stock Holding History

C.M. Bidwell & Associates’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-79
Closed -$546 – 547
2026
Q1 		$546 Buy
+79
New +$609 ﹤0.01% 463
2021
Q3 		– Sell
-2,510
Closed -$54K – 620
2021
Q2 		$54K Sell
2,510
-70
-3% -$1.25K 0.04% 297
2021
Q1 		$39K Sell
2,580
-100
-4% -$1.62K 0.03% 317
2020
Q4 		$35K Buy
+2,680
New +$32.3K 0.03% 313

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

C.M. Bidwell & Associates's VNDA Position: Q2 2026 in Review

C.M. Bidwell & Associates sold out of Vanda Pharmaceuticals (VNDA) in Q2 2026, closing a stake of 79 shares — an estimated $546 sold.

C.M. Bidwell & Associates first reported a position in VNDA in Q4 2020 and held it in 4 quarters. The position peaked at $54K in Q2 2021. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • C.M. Bidwell & Associates reported no remaining Vanda Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 79 Vanda Pharmaceuticals shares in Q2 2026, an estimated $546.
  • C.M. Bidwell & Associates first reported a position in Vanda Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • C.M. Bidwell & Associates's Vanda Pharmaceuticals position peaked at $54K in Q2 2021.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.